

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001759241
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Disc Medicine, Inc.
SEC File Number 001-39438
Address of Issuer 321 ARSENAL STREET, SUITE 101
WATERTOWN
MASSACHUSETTS
02472
Phone (617) 674-9274
Name of Person for Whose Account the Securities are To Be Sold Atlas Venture Opportunity Fund I, L.P.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer 10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	BTIG, LLC 600 Montgomery Street 6th Floor San Francisco CA 94111	82500	5625675.00	24140428	01/23/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Common Stock 10/07/2020 Private Placement	Issuer	<input type="checkbox"/>	82500	10/07/2020 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Opportunity Fund I, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/12/2023	51967	3263405.22
Atlas Venture Opportunity Fund I, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/13/2023	3548	212875.15
Atlas Venture Opportunity Fund I, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/14/2023	20549	1197518.68
Atlas Venture Opportunity Fund I, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	01/10/2024	20000	1280000.00
Atlas Venture Fund X, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/12/2023	77951	4895139.23
Atlas Venture Fund X, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/13/2023	5323	319372.72
Atlas Venture Fund X, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	12/14/2023	30825	1796365.93
Atlas Venture Fund X, L.P. 300 Technology Square 8th Floor Cambridge MA 02139	Common Stock	01/10/2024	30000	1920000.00

144: Remarks and Signature

Remarks

Date of Notice 01/23/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading

instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Atlas Venture Opportunity Fund I, L.P., By: /s/ Ommer Chohan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)